Consolidated federal litigation over Nexium is dead after a California federal judge entered judgment in favor of AstraZeneca Pharmacueticals L.P. and McKesson Corp.
U.S. District Judge Dale Fischer of the Central District of California said the 20-odd plaintiffs in the centralized federal multidistrict litigation “shall recovery nothing” and must pay the defendants’ lawsuit costs. She granted summary judgment for the defense.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
